{"id":44507,"date":"2022-05-31T15:01:32","date_gmt":"2022-05-31T13:01:32","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/"},"modified":"2022-05-31T15:01:32","modified_gmt":"2022-05-31T13:01:32","slug":"oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/","title":{"rendered":"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors"},"content":{"rendered":"
\n

BILBAO, Spain–(BUSINESS WIRE)–After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment.\n<\/p>\n

<\/a><\/p>\n

\nOMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance and immunosuppression.\n<\/p>\n

\nOMTX705 has already shown unbeatable safety in non-human primates and tumor regression in murine models of pancreatic, breast, lung and gastric cancer.\n<\/p>\n

\nOncomatryx will run a multicenter, dose escalation trial in patients suffering metastatic solid tumors. OMTX705 will be administered as single agent and in combination with immunotherapy.\n<\/p>\n

\nOMTX705 phase I clinical trial will be run in seven hospitals in USA and Spain.\n<\/p>\n

\nAbout Oncomatryx<\/b>\n<\/p>\n

\nOncomatryx, a global biopharmaceutical company, is pioneering the development of precision ADCs and bispecific antibodies against novel targets in the tumor microenvironment.\n<\/p>\n

\nThe company, located in the Bizkaia Technology Park (Bilbao, Spain), has discovered novel pathways and proteins in the Cancer-Associated Fibroblasts that surround the tumor and promote its invasiveness, immunosuppression and drug resistance.\n<\/p>\n

\nOncomatryx has undertaken the development of pioneering drugs against these pathways and proteins of the tumor microenvironment, in collaboration with prestigious universities and hospitals in USA and Europe, led by the Institute of Cell Biology and Immunology of the University of Stuttgart (Germany).\n<\/p>\n

\nOncomatryx is investing 50 million euros in 2022-2024, to develop OMTX705 and other novel tumor microenvironment-targeted ADCs and Bispecific antibodies.\n<\/p>\n

\nwww.oncomatryx.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPedro Esnaola
\n
admin@oncomatryx.com<\/a>
+34 946 087 037\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BILBAO, Spain–(BUSINESS WIRE)–After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment. OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44507","6":"format-standard","7":"category-industry"},"yoast_head":"\nOncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BILBAO, Spain–(BUSINESS WIRE)–After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment. OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-31T13:01:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220524005142\/en\/1464030\/21\/logo_OMTX_HD_-_copia.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors\",\"datePublished\":\"2022-05-31T13:01:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/\"},\"wordCount\":280,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005142\\\/en\\\/1464030\\\/21\\\/logo_OMTX_HD_-_copia.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/\",\"name\":\"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005142\\\/en\\\/1464030\\\/21\\\/logo_OMTX_HD_-_copia.jpg\",\"datePublished\":\"2022-05-31T13:01:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005142\\\/en\\\/1464030\\\/21\\\/logo_OMTX_HD_-_copia.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005142\\\/en\\\/1464030\\\/21\\\/logo_OMTX_HD_-_copia.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors - Pharma Trend","og_description":"BILBAO, Spain–(BUSINESS WIRE)–After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment. OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-31T13:01:32+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220524005142\/en\/1464030\/21\/logo_OMTX_HD_-_copia.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors","datePublished":"2022-05-31T13:01:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/"},"wordCount":280,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524005142\/en\/1464030\/21\/logo_OMTX_HD_-_copia.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/","url":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/","name":"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524005142\/en\/1464030\/21\/logo_OMTX_HD_-_copia.jpg","datePublished":"2022-05-31T13:01:32+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220524005142\/en\/1464030\/21\/logo_OMTX_HD_-_copia.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220524005142\/en\/1464030\/21\/logo_OMTX_HD_-_copia.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/oncomatryx-announces-fda-and-aemps-ind-clearance-for-omtx705-a-first-in-class-tumor-microenvironment-targeted-adc-to-treat-advanced-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44507"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44507\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}